The Ann Arbor pharma startup Lycera Corp. Tuesday announced a collaboration with pharma giant Merck to discover, developand commercialize small-molecule therapies directed at novel targets to treat a broad range of immune system disorders.
Lycera Corp., a biopharmaceutical company creating innovative approaches to developing novel oral medicines to treat autoimmune diseases, today announced that it has reached the first milestone under its research collaboration with Merck, triggering a milestone payment.
Nanobio Corp. Thursday announced a preclinical collaboration with a subsidiary of Merck & Co. Inc. focused on the development of a vaccine for Respiratory Syncytial Virus (RSV).
The first Habitat for Humanity house built as part of the ‘Build Smart, Breathe Easier’ national asthma education program will be dedicated in partnership with the Dunmore family in Detroit on Friday, July 29.
The Plymouth-based biopharmaceutical developer Lycera Corp. Thursday announced an exclusive research collaboration with pharma giant Merck to develop drug candidates that have the potential to treat major autoimmune diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis
Allegan-based Perrigo Co. (Nasdaq: PRGO) announced that it has filed with the U.S. Food and Drug Administration an Abbreviated New Drug Application for omeprazole 20mg/sodium bicarbonate 1100mg, the generic equivalent of Zegerid OTC, and that […]